Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 367

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Co-Delivery of siRNA and An Anticancer Drug for Treatment of Multidrug-Resistant Cancer

Open access
Saad, Maha, Garbuzenko, Olga B, Minko, Tamara·2008·Nanomedicine

Abstract

AIMS: To develop a novel nanomedicine approach for the treatment of multidrug-resistant (MDR) cancer by combining an anticancer drug and suppressors of cellular resistance within one multifunctional nanocarrier-based delivery system (NDS). MATERIALS & METHODS: The NDS consisted of cationic liposomes (carrier, 100-140 nm), doxorubicin (DOX, anticancer drug), siRNA targeted to MRP1 and BCL2 mRNA (suppressors of pump and nonpump cellular-resistance, respectively). The resulting approximately 500 nm complex has a zeta potential of +4 mV. RESULTS & DISCUSSION: The NDS provides an effective co-delivery of DOX and siRNA as well as cell-death induction and suppression of cellular resistance in MDR lung cancer cells. CONCLUSION: We demonstrate NDS-enhanced efficiency of chemotherapy to a level that cannot be achieved by applying its components separately.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2217/17435889.3.6.761

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 367

Metadata

Authors
Saad, M., Garbuzenko, O. B., & Minko, T.
Venue
Nanomedicine
Published
2008-11-24
Volume
3
Issue
6
Pages
761-776
ISSN
  • 1743-5889 (ISSN-L)
  • 1748-6963
OpenAlex
W2150702593
Cited by
367
References
3
FWCI
5.18
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Co-Delivery of siRNA and An Anticancer Drug for Treatment of Multidrug-Resistant Cancer. https://app.cochat.ai/papers/10.2217/17435889.3.6.761
The paper
Saad, M., Garbuzenko, O. B., & Minko, T. (2008). Co-Delivery of siRNA and An Anticancer Drug for Treatment of Multidrug-Resistant Cancer. Nanomedicine. https://doi.org/10.2217/17435889.3.6.761

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.